---
title: Antidepressants
author: J. Austin Straley, DO
layout: post
chapter: 9
section: 01
lesson: 8
date: 2023-03-30
---

- Selective Serotonin Reuptake Inhibitors (SSRIs)
  - Notes:
    - Increased risk of suicide in 0-24 y/o upon initiation (black box)
    - More gestures and Ideations, no more completions
    - Decreased risk of suicide in ≥65 y/o upon initiation (white men)
  - Drug Interactions:
    - Paroxetine ≥ Sertraline ≥ Citalopram
    - Also helpful for anxiety associated depression
  - SE (General):
    - Sexual dysfunction is the MCC of noncompliance and MC SE (50-80%)
    - Akathisia
    - Early: HA/Nausea, dizziness, insomnia, anxiety
    - Nonspecific: Flu-like, GI upset, Psych symptoms
    - Late: sexual dysfunction and weight gain
  - Citalopram (Celexa)
    - Dose: 20mg up to 20-40mg daily (40mg max effective)
    - Weak CYP2D6 inhibitor
    - Use:
      - Treats anxiety symptoms better than other SSRIs
      - Least likely to have drug interaction
      - Low P450
    - SE: More cardiotoxic, May Prolong Qt interval (blockade of KCNH2 gene potassium channel)
      - 20mg: 8.5ms, 40mg: 12.6ms, 60mg: 18.5ms
      - Use 20mg if ≥60 or hepatic dysfunction
  - Escitalopram (Lexapro)
    - Dose: 10mg up to 10-20mg daily (10mg max effective)
    - Most serotonin specific of SSRIs
      - Most potent SSRI
    - Use: Paraphilias, GAD, Chronic pain
      - Post-MI depression due to low drug reaction potential
      - Low p450, fewer SE than citalopram, rapid
    - SE: QTc Prolongation: 10mg: 4.5ms, 20mg: 6.6ms, 30mg: 10.7ms
  - Fluoxetine (Prozac)
    - Dose: 20mg up to 20-80mg daily
    - Potent CYP2D6 inhibitor
    - Use: OCD, Bulimia, Panic Disorder
      - Can be used with olanzapine for acute bipolar depression
      - Doesn't need to be tapered when stopping, long half-life
    - SE: May cause agitation/anxiety and insomnia initially, sexual dysfunction, may cause weight loss
      - Nausea, vomiting, diarrhea
      - QTc prolongation (4.5ms)
  - Fluvoxamine (Luvox)
    - 50mg daily, max 300mg divided daily
    - CYP3A4, 2C10, 1A2 inhibitor
      - Most drug interations
    - Use: OCD only
      - No QTc Prolongation (-5.0ms)
  - Paroxetine (Paxil)
    - Dose: 20mg up to 20-60mg daily (50mg max effective)
    - Potent CYP2D6 inhibitor
    - Use: Premature ejaculation, Body dysmorphic disorder, SAD, OCD, PTSD
    - Potent CYP2D6 inhibitor
      - No QTc prolongation
    - SE: Most likely to have side effects, Dizziness, most sedating and anticholinergic SSRI, highest rate of sexual dysfunction, higher rate of weight gain (30%), highest rate of discontinuation syndrome, sedating, constipation
      - Cardiac septal defects in kids (pulm htn)
  - Sertraline (Zoloft)
    - Dose: 50mg up to 50-200mg daily
      - Increased absorption with food
    - Weak CYP2D6
    - Use: PMDD, PTSD, SAD, OCD, Post-MI
      - Best for breastfeeding
    - SE: delayed ejaculation, QTc Prolongation, Bruxism (better with buspirone), generic may be activating, bruising, hair loss
      - 3.0ms
      - Most likely to cause GI upset (Nausea ≥ Diarrhea)
      - May displace warfarin increasing PTT
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  - Notes:
    - Nausea (MC), Sexual dysfunction, Hypertension (not duloxetine), Pseudo-anticholinergic effects (constipation, dizziness, dry mouth, sweating, agitation, anxiety, tachycardia) due to increased synaptic NE
  - Duloxetine (Cymbalta)
    - Dose: 20 mg up to 60mg daily (BID dosing may decrease SE)
      - Aka Yantreve
    - MOA: 5HT = NE at all doses
      - Moderate CYP2D6
    - Use: MDD, stress incontinence, panic disorder
      - FDA approved for diabetic neuropathy, fibromyalgia
      - Pain with depression
      - Useful in diabetics with peripheral neuropathic pain
      - Rapid symptom relief, few side effects
      - Only SNRI w/o BP effects
    - SE: Avoid in renal failure, Hepatic failure in liver disease, may increase HbA1c, Insomnia
      - Nausea, dry mouth, constipation
      - Prompt discontinuation due to side effects
      - Less likely to cause HTN
  - Desvenlafaxine (Pristiq)
    - Dose: 50mg daily
    - MOA: Inhibits 5HT and NE
      - Active metabolite of venlafaxine and levo-milnacipran
      - Avoids hepatic CYP2D6 metabolism
      - Less likely to increase BP than Effexor
    - Use: MDD, GAD, Panic Disorder, Menopause, Cocaine dependence
      - Rapid, few side effects, low cytochrome P-450 effects
      - No Weight gain
  - Milnacipran
    - Racemic mixture of levo- and dextro-milnacipran
    - Use: Fibromyalgia (FDA)
      - No CYP450 interaction, NET ≥SERT selectivity
    - SE: HTN, Tachycardia, GI symptoms, hyperhidrosis, ED
  - Levo-Milnacipran (Fetzima)
    - 20mg; max 40-120mg daily
    - Use: MDD
      - More potent enantiomer of milnacipran
      - Inhibits BACE-1 (B-amyloid plaques)
    - SE: HTN, Tachycardia, GI symptoms, hyperhidrosis, ED
  - Venlafaxine (Effexor)
    - Dose: 37.5mg up to 75-375mg daily XR
    - MOA: Inhibits 5HT ≥ NE low dose, NE ≥ 5HT at high dose
      - Inhibits CYP2D6
    - Use: MDD, GAD, Panic Disorder, Menopause, Cocaine dependence
      - Rapid, few side effects, low cytochrome P-450 effects
      - No Weight gain
    - SE: May cause diastolic hypertension, activating, "stimulant effect", Increases diastolic BP, most cardiotoxic SNRI, headache, constipation, sweating, Anxiety and HTN in high doses, discontinuation syndrome
      - Nausea and sexual side effects in 30% due to NE not 5HT
      - May have withdrawal
- Atypical Antidepressants
  - Bupropion (Wellbutrin)
    - Dose: 150mg up to 300-450mg daily
    - MOA: NE and Dopamine reuptake inhibitor, increasing activity
      - Metabolized by CYP2B6 to hydroxy- which is a moderate CYP2D6 inhibitor
      - CYP2B6 substrate
    - Use: Smoking cessation, MDD w/seasonal pattern, Adult ADHD, Obesity
      - Good for weight loss, hypersomnia, smoking cessation, no sexual side effects
      - Not good for anxious patients
    - SE: Agitation, insomnia, anorexia, sweating, false positive for amphetamines on UDS, headache, tremor, dry mouth, psychosis
      - Avoid in pregnancy
    - CI: Seizures, Bulimia and Anorexia Nervosa, epilepsy
      - Check for hypokalemic, hypochloremic metabolic alkalosis (self-induced vomiting seen in Bulimia Nervosa) prior to initiating
      - Seizure risk is 2% at 600mg, 0.1% with 300-450mg, almost same as other antidepressants (0.05%)
  - Mirtazapine (Remeron)
    - Dose: 7.5mg up to 15-45mg daily
      - \<30mg = sedation
      - ≥30mg = activating (more NE)
    - MOA: Presynaptic Alpha-2 antagonist
        - Increased NE and 5-HT release
      - Selective postsynaptic 5-HT receptor antagonist
        - Increased 5-HT1 receptor neurotransmission, antagonist at 5-HT2 and 5-HT3 receptor
      - Antagonizes H1 receptors
      - Clearance impaired in liver disease by 30%, 50% in renal disease, elderly (males 40%, females 10%)
    - Use: Insomnia
      - Sleep, Depression, Hunger (Weight Gain)
      - Don't break it in half, sedative already
      - Additive effects with alcohol and benzos (substrate)
      - Increases appetite, weight gain, increases mood, sleep
        - Lacks sexual side effects
    - SE: Drowsiness (54%), Xerostomia (25%), Weight Gain (12%), Sedation, Thrombocytopenia, Bone marrow suppression and neutropenia, hypertriglyceridemia, increase in appetite, constipation (13%), Disorientation and tachycardia, increased cholesterol, decreased ANC
  - Maprotiline (Ludiomil)
    - D2 blocker (NET ≥SERT inhibition)
    - TCA like adverse effects, seizures, high NET affinity
    - Use: Anxiety with depressive features
  - Nefazodone (Serzone)
    - 50mg BID up to 300mg BID
    - 5-HT2A antagonists (relatively selective), Alpha1 receptor blockade, CYP3A4 inhibitor, weak Serotonin reuptake inhibitor (antagonist and agonist of serotonin receptor)
    - Sedation, dose related GI effects \< SSRIs
    - Rare sexual effects, hypotension
      - Short half life
    - Use: Insomnia
    - Black Box Warning: Fulminant liver failure
  - Trazodone (Desyrel)
    - MOA: 5-HT2A antagonist (relatively selective), Alpha-1 receptor blockade, CYP3A4 substrate, 5HT2C receptor agonist
      - Vasodilation, Short half life
    - Use: Insomnia in depression
      - Depression: 150mg up to 150-600mg daily
      - Sleep: 25-50mg qPM
    - Pronounced sedation, dose related GI effects \< SSRIs
    - SE: Rare sexual effects, priapism (\<1%), hypotension, sedation
  - Vilazodone (Viibryd)
    - Dose: 10mg daily, goal 40mg daily, 10mg per week increase
    - SSRI + 5HT1 partial agonist (MDD + GAD)
      - CYP3A4
    - Use:
      - Less Sexual and Weight gain SE
    - SE: Nausea and Diarrhea ≥ SSRIs, discontinuation syndrome
  - Vortioxetine (Trintellix)
    - Serotonergic, nausea, Sexual side effects
    - Processing speed increase
    - SSRI + 5HT1A full agonist/5HT1B partial agonist, 5-HT3/7/1D antagonist
- Monoamine Oxidase Inhibitors (MAOIs)
  - Avoid: beer, wine, aged cheese, soy sauce, bananas, smoked meat
  - SE: MCly Orthostatic hypotension and weight gain, paresthesia (from B6 deficiency), mania
    - highest rates of sexual dysfunction of all antidepressants, Anorgasmia
    - Activation, insomnia, and restlessness
    - Confusion at higher doses
    - Hypertensive Crisis (0.02%)
    - Delirium-like discontinuation with psychosis, excitement, and confusion
      - Meperidine is specifically contraindicated
    - Need 2-week washout
  - Nonselective
    - MOA: Irreversibly inhibit MAOA/B
    - Isocarboxazid (Marplan)
      - 10mg BID, max 60mg daily
      - Use: Geriatric Depression
    - Tranylcypromine (Parnate)
      - 30mg daily to 60mg in divided doses
      - Use: Atypical Depression
    - Phenelzine (Nardil)
      - 15mg TID to 90mg TID
      - Non-selective blockade of MAO
      - More sedating than selegiline and tranylcypromine
      - Pain, Eating, Panic disorders
  - Selective
    - Selegiline (Emsam)
      - Dose: 6mg-12mg transdermal patch (24hr)
      - MOA: MAO-B irreversible inhibition at low doses
          - Increased dopamine
        - MAO-A inhibition if given transdermally
      - Use: Parkinson's drug
        - No dietary restriction if used in low dosages
      - SE: Orthostatic hypotension
    - Rasagiline
- Tricyclic Antidepressants (TCAs)
  - General
    - MOA: Block NE and serotonin reuptake at synapse, some block Dopamine reuptake
      - Inhibition of NE and 5-HT can trigger convulsions/seizures
      - Also block muscarinic acetylcholine receptors
        - Orthostatic hypotension due to alpha blockade
        - H1 receptors also blocked
      - Class 1A Antiarrhythmic agents at low doses, arrhythmic agents at high doses
    - 2nd MCC of lethal OD in US (amitriptyline ≥ rest combined), death in 8.5/1000 OD
    - SE: Convulsions, Coma, Cardiotoxicity, Respiratory Depression, Hyperpyrexia, Prolonged QRS, weight gain, sedation
      - Cholinergic rebound on discontinuation (flu like)
      - Delirium (amitriptyline)
      - Seizures (2% clomipramine)
      - Acute Hepatitis (0.1%)
    - CI: Narrow-angle Glaucoma
  - Secondary Amines
    - General
      - High affinity for blocking NE reuptake (NE ≥ 5HT)
      - Fever, anticholinergic effects, weight gain
    - Desipramine (Norpramin)
      - Dose: 25-50mg daily up to 100-300mg daily
      - Least sedating TCA (most noradrenergic)
      - SE: LFT elevation (AST≥≥≥ALT)
    - Maprotiline (Ludiomil)
      - Dose: 25mg TID, max 225mg daily
      - Lacks 5HT reuptake inhibition (mainly NE reuptake)
      - SE: Sedating
    - Nortriptyline (Pamelor)
      - Dose: 25-50mg daily up to 150-200mg daily
      - Use: Elderly depression, cardiac diseases, pruritus, smoking cessation, QTc Prolongation
        - Least likely to cause orthostatic hypotension (low acnticholinergic)
  - Tertiary Amines
    - Notes:
      - 5HT ≥ NE
      - Have more anticholinergic side effects and sedation
      - Agitation, blurry vision, fever, constipation, urinary retention, confusion
      - Myotonic jerking, delirium, sedation, coma
    - Amitriptyline (Elavil)
      - Dose: 25-50mg daily up to 100-200mg daily
      - Use: Depression w/insomnia, chronic pain
      - SE: Orthostatic hypotension (causing falls), Sedating
        - Semiannual EKG due to risk of QT prolongation
        - Most anticholinergic
    - Amoxapine (Asendin)
      - Dose: 50mg BID, max 400mg daily
      - MOA: D2 blocker (5HT = NE, weak DA)
        - Blockade of NE and 5-HT reuptake
      - Use: MDD w/Psychotic Features
        - Dopamine receptor blockade (antidepressant)
          - Anti-dopaminergic effects (Parkinson's, ED)
          - Unique to drug in class (may cause EPS)
      - SE: higher seizure risk, TD
        - Most dangerous in overdose
    - Clomipramine (Anafranil)
      - Dose: 25mg daily, max 250mg daily
      - Most serotoninergic, most sexual effects
      - Use: OCD
    - Doxepin (Sinequan)
      - Dose: 25-75mg daily up to 100-300mg daily
      - MOA: 5HT = NE, highly sedation
        - Most antihistamine
      - Use: GAD, PUD, pruritis
      - SE: Sedating, antihistaminergic, anticholinergic
    - Imipramine (Tofranil)
      - Dose: 25-50mg daily up to 100-200mg daily
      - MOA: 5HT = NE
      - Use: Panic disorder with agoraphobia, enuresis, eating disorders, but has a high relapse rate
      - SE: Orthostatic hypotension, prolonged QT, LFT elevation (AST≥≥≥ALT)
    - Protriptyline (Vivactil)
      - Less sedating than doxepin, nor/amitriptyline, imipramine
      - Good for job alertness